LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Closed

Sector Healthcare

84.61 -1.23

Buy Sell

Overview

Share price change

24h

Current

Min

83.88

Max

85.64

Key metrics
By Trading Economics
Income	68M 89M
Sales	2.8M 649M
P/E Sector Avg	100.39 79.786
EPS	0.71
Profit margin	13.661
Employees	3,401
EBITDA	81M 136M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+24.16 upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2024

Market Stats
By TradingEconomics
Market Cap	683M 16B
Previous open	85.84
Previous close	84.61

News Sentiment

By Acuity

100%

345 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

84.23 / 85.75 Support & Resistance

BioMarin Pharmaceutical Inc Chart

Related News

10 Jun 2024, 17:41 UTC

Major Market Movers

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

Peer Comparison

Price change

BioMarin Pharmaceutical Inc Forecast

Price Target

By TipRanks

24.16% upside

12 Months Forecast

Average 105.08 USD 24.16%

High 130 USD

Low 72 USD

Based on 13 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to BioMarin Pharmaceutical Inc - Dist in the past 3 months.

Technical Score

By Trading Central

84.23 / 85.75Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

345 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.